Impact of Dialysis Modality on Hepcidin and Iron Metabolism
- Conditions
- End-stage Renal Disease
- Registration Number
- NCT01723111
- Lead Sponsor
- Kyungpook National University Hospital
- Brief Summary
* Dialysis modality may influence the oxidative stress and proinflammatory cytokines in ESRD patients.
* Dialysis modality may affect hepcidin
* Dialysis modality may influence iron and ESA requirements.
- Detailed Description
It has been considered that PD patients tended to be less anemic and require lower ESA dose than HD patients. In addition, it was also known that the level of oxidative stress and inflammatory cytokines tended to be lower in PD patients than HD patients. And hepcidin synthesis is markedly increased during inflammation. Altogether, Lower ESA requirement in PD patients may be associated with lower hepcidin level due to lower inflammatory state compared with HD patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
- Written informed consent
- Age 18 years or older
- Dialysis treatment was expected over 3 months
- In HD patients, regular hemodialysis 4 h a session more than two times a week
- In PD patients, over 2 exchange with more than 1.5 L solution
- Poorly controlled hypertension, i.e. sitting blood pressure exceeding 180/110 despite medication requiring hospitalization or interruption of ESA treatment
- Significant acute or chronic bleeding such as overt gastrointestinal bleeding within the previous 3 months
- Active malignant disease (except non-melanoma skin cancer and patients with malignant disease who have been disease-free for at least the 5 previous years are eligible)
- Acute infection
- Hemolysis
- Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
- Megaloblastic anemia
- Platelet count >500 x 109/L or <100 x 109/L
- Pure red call aplasia
- Epileptic seizure during previous 3 months
- Women of childbearing potential without effective contraception
- Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol
- Planned elective surgery during the study period except for cataract surgery or laser photocoagulation
- Life expectancy less than 12 month
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ESA (Erythrocyte stimulating agents) dose six months We will compare ESA dose between PD patients and HD patients
- Secondary Outcome Measures
Name Time Method Hepcidin level six months We will compare hepcidin level between PD patients and HD patients
hs-CRP six months We will compare hs-CRP level between PD patients and HD patients
IL-6 six months We will compare IL-6 between PD patients and HD patients
Total antioxidant capacity six months We will compare total antioxidant capacity between PD patients and HD patients
IV iron treatment (% of patients) six months We will compare IV iron treatment (% of patients) between PD patients and HD patients
Transfusion rate six months We will compare transfusion rate ( % of patients) between PD patients and HD patients
Myeloperoxidase six months We will compare myeloperoxidase between PD patients and HD patients
TNF-a six months We will compare TNF-a between PD patients and HD patients
Trial Locations
- Locations (4)
Yeungnam University College of Medicine
🇰🇷Daegu, Korea, Republic of
Daegu Fatima Hospital
🇰🇷Daegu, Korea, Republic of
Dongsan Medical Center
🇰🇷Daegu, Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of